Related Experiment Video

Updated: Aug 10, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
08:04

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method

Published on: October 23, 2018

IRS-1: auditing the effectiveness of mTOR inhibitors

John B Easton1, Raushan T Kurmasheva, Peter J Houghton

  • 1Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.

Cancer Cell
|March 15, 2006
PubMed

Insights

Rapamycin analogs show promise against lymphomas but struggle with solid tumors. New research reveals feedback mechanisms and hypoxia impacts, offering strategies to improve mTOR inhibitor effectiveness in cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • mTOR inhibitors (rapalogs) demonstrate antitumor effects in lymphomas.
  • Limited success of rapalogs in solid tumors necessitates further investigation.
  • Understanding resistance mechanisms is crucial for optimizing cancer treatment.

Purpose of the Study:

  • To elucidate the mechanisms behind poor response to rapamycin analogs in solid tumors.
  • To explore the role of feedback inhibition and pathway activation in rapalog resistance.
  • To investigate the potential of targeting hypoxic cells with mTOR inhibitors.

Main Methods:

  • Analysis of mTOR-mediated feedback inhibition of insulin receptor substrate 1.
  • Assessment of Akt-mediated survival signaling in response to rapamycin.
  • Investigation of pathway activation's impact on hypoxia-mediated mTOR signaling downregulation.

Main Results:

  • Rapamycin treatment can relieve feedback inhibition of insulin receptor substrate 1, activating pro-survival Akt.
  • Hypoxia influences mTOR signaling, suggesting differential drug response in hypoxic tumor regions.
  • These findings provide insights into resistance mechanisms and potential therapeutic strategies.

Conclusions:

  • Targeting feedback loops and exploiting hypoxic vulnerabilities may enhance rapalog efficacy in solid tumors.
  • Further research into mTOR signaling pathways is essential for developing more effective cancer therapies.
  • Rapalogs may be repurposed to selectively target hypoxic tumor cells.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Polysome Fractionation and Analysis of Mammalian Translatomes on a Genome-wide Scale10:56

Polysome Fractionation and Analysis of Mammalian Translatomes on a Genome-wide Scale

Published on: May 17, 2014

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...